Fig. 4.

a Representative small animal maximum intensity projection (MIP) [¹⁸F]FDG and [⁶⁴Cu]Cu-LLP2A PET images in disseminated U266-CG tumor mice (treated and untreated) as well as in no tumor mouse cohorts, respectively. Bortezomib therapy was started in the treatment cohort between weeks 0–1. White arrows are pointing to the selected focal tumor lesions in the treated and untreated mice imaged with [⁶⁴Cu]Cu-LLP2A/PET. Scale Bar ([¹⁸F]FDG): Min 4% ID/cc, Max 8% ID/cc; Scale Bar ([⁶⁴Cu]Cu-LLP2A): Min 3% ID/cc, Max 6% ID/cc. b [¹⁸F]FDG and [⁶⁴Cu]Cu-LLP2A PET quantification (SUV_mean) of the bone marrow rich organs—spine, right (Rt) femur and left (Lt) femur, in U266-CG disseminated tumor model and no tumor mice at week 0 (baseline, before therapy was started). c [¹⁸F]FDG SUV fold-change from baseline in the spine, right (Rt) femur and left (Lt) femur in U266-CG tumor (treated and untreated) mice and no tumor mice, plotted as a function of time. d [⁶⁴Cu]Cu-LLP2A SUV fold-change from baseline in the spine, right (Rt) femur and left (Lt) femur in U266-CG tumor mice (treated and untreated) and no tumor mice, plotted as a function of time. *p ≤ 0.05, **p ≤ 0.01